Journal article · 2016 · Open access

Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods

Lada Leyens, Angela M. Brand

Public Health Genomics, 19(3), 187–191 · Published 30 May 2016 · DOI 10.1159/000446537

Open PDFView at the publisherCite this paper

In brief

“Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods” is a 2016 journal article by Lada Leyens and Angela M. Brand, published in Public Health Genomics. OpenAlex counts 38 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Public Health Genomics.

Citations
38
Most cited in
2018 (6)
Field-weighted impact
9.06
References
6
Authors
2

Abstract

National and international medicines agencies have developed innovative methods to expedite promising new medicines to the market and facilitate early patient access. Some of these approval pathways are the conditional approval and the adaptive pathways by the European Medicines Agency (EMA); the Promising Innovative Medicine (PIM) designation and the Early Access to Medicines Scheme (EAMS) by the Medicines and Healthcare Products Regulatory Agency (MHRA), as well as the Fast Track, Breakthrough or Accelerated Approval methods by the Food and Drug Administration (FDA). However, at least in Europe, these methods cannot achieve the goal of improving timely access for patients to new medicines on their own; the reimbursement process also has to become adaptive and flexible. In the past 2 years, the effective access (national patient access) to newly approved oncology drugs ranged from 1 to 30 months, with an extremely high variability between European countries. The goal of early patient access in Europe can only be achieved if the national health technology assessment bodies, such as NICE (ENG), HAS (FR), G-BA (DE) or AIFA (IT), provide harmonized, transparent, flexible, conditional and adaptive methods that adopt the level of evidence accepted by the medicines agencies. The efforts from medicines agencies are welcome but will be in vain if health technology assessments do not follow with similar initiatives, and the European 'postcode' lottery will continue.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Leyens, L., & Brand, A. M. (2016). Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods. Public Health Genomics, 19(3), 187–191. https://doi.org/10.1159/000446537

MLA 9

Leyens, Lada, and Angela M. Brand. “Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.” Public Health Genomics, vol. 19, no. 3, 2016, pp. 187–191. https://doi.org/10.1159/000446537.

Chicago

Leyens, Lada and Angela M. Brand. 2016. “Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.” Public Health Genomics 19 (3): 187–191. https://doi.org/10.1159/000446537.

Harvard

Leyens, L. and Brand, A. M. (2016) ‘Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods’, Public Health Genomics, 19(3), pp. 187–191. doi:10.1159/000446537.

IEEE

L. Leyens and A. M. Brand, “Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods,” Public Health Genomics, vol. 19, no. 3, pp. 187–191, 2016, doi: 10.1159/000446537.

BibTeX

@article{leyens2016early,
  title     = {{Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods}},
  author    = {Leyens, Lada and Brand, Angela M.},
  journal   = {Public Health Genomics},
  year      = {2016},
  volume    = {19},
  number    = {3},
  pages     = {187--191},
  doi       = {10.1159/000446537},
  url       = {https://doi.org/10.1159/000446537}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201644
201755
201866
201955
202011
202155
202233
202355
202433
202511

Its field-weighted citation impact is 9.06: it has been cited 9.06 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy

  • health technology assessment
  • conditional approval
  • adaptive pathways
  • accelerated approval
  • oncology drugs
  • level of evidence

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Leyens, L., & Brand, A. M. (2016). Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods. Public Health Genomics, 19(3), 187–191. https://doi.org/10.1159/000446537

How many times has this paper been cited?

38 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Public Health Genomics: sign in and open the PDF from this page.

Who wrote this paper?

Lada Leyens, Angela M. Brand.

What is the DOI of this paper?

10.1159/000446537, permanently at https://doi.org/10.1159/000446537. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.